Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) CFO Christopher Cline sold 310 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $13,624.50. Following the completion of the transaction, the chief financial officer owned 118,658 shares of the company’s stock, valued at $5,215,019.10. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Travere Therapeutics Stock Performance
TVTX stock opened at $44.70 on Thursday. The company has a debt-to-equity ratio of 3.16, a current ratio of 3.13 and a quick ratio of 2.70. The company has a 50 day moving average price of $32.59 and a 200 day moving average price of $32.83. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $48.61. The stock has a market capitalization of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm had revenue of $127.20 million during the quarter, compared to analysts’ expectations of $136.23 million. During the same quarter in the previous year, the company posted ($0.47) EPS. Travere Therapeutics’s revenue was up 55.6% on a year-over-year basis. Analysts forecast that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.
Hedge Funds Weigh In On Travere Therapeutics
Wall Street Analysts Forecast Growth
TVTX has been the subject of a number of analyst reports. Canaccord Genuity Group lifted their target price on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. TD Cowen lifted their target price on shares of Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen lowered shares of Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. HC Wainwright lifted their target price on shares of Travere Therapeutics from $47.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Citigroup lifted their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.83.
Check Out Our Latest Report on TVTX
Travere Therapeutics News Roundup
Here are the key news stories impacting Travere Therapeutics this week:
- Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
- Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
- Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year‑over‑year, providing fundamental support for the analyst upgrades and investor optimism. No link
- Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
- Neutral Sentiment: HC Wainwright slightly trimmed long‑term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
- Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
- Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre‑arranged Rule 10b5‑1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500‑share sale) can create short‑term selling pressure or investor concern. Example SEC filing: CEO Form 4
Travere Therapeutics Company Profile
Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.
The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.
See Also
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
